Inflammatory pain in Nav1.7R-/-. (A) Analysis of behavior of fNav1.7 (white) and Nav1.7R-/- (black) mice in models of inflammatory pain. (Aa) Pain behavior of fNav1.7 (n = 14) and Nav1.7R-/- (n = 17) mice after intraplantar injection of 20 μl of 5% formalin. Time spent licking/biting the injected hindpaw in phase I (1-10 min) and phase II (10-55 min) was recorded. There is a reduction in phase I (P = 0.03, t test) (fNav1.7, 93.1 ± 7.2; Nav1.7R-/-, 70.4 ± 6.6). In phase II, Nav1.7R-/- mice also showed a significant reduction in pain behavior (P = 0.004, t test) (101.3 ± 18.9 and 220.9 ± 34.8 respectively). (Ab) Time course of the formalin response (P < 0.05 at 5-, 20-, 25-, and 30-min time points). (Ac) Thermal hyperalgesia after intraplantar injection of 20 μl of CFA. fNav1.7 mice developed pronounced hyperalgesia (0.56 ± 0.1, n = 9) from day 1, whereas Nav1.7R-/- mice did not (0.97 ± 0.06, n = 14) (P < 0.001, ANOVA; P < 0.05 at all time points). (Ad) Mechanical allodynia induced by intraplantar injection of 20 μl of CFA. fNav1.7 mice developed pronounced allodynia from day 1 (0.50 ± 0.16, n = 8), whereas the Nav1.7R-/- mice did not (1.05 ± 0.12, n = 13) (P = 0.012, ANOVA; P < 0.05 at days 2, 3, 4, and 10). (Ae) Thermal hyperalgesia after intraplantar injection of 20 μl of 2% carrageenan. fNav1.7 mice developed pronounced hyperalgesia (0.47 ± 0.03, n = 7) within an hour, whereas Nav1.7R-/- mice did not (1.07 ± 0.04, n = 5) (P < 0.001, ANOVA; P < 0.05 at all time points). (Af) Thermal hyperalgesia after intraplantar injection of 500 ng of NGF. fNav1.7 mice (n = 15) developed thermal hyperalgesia in a biphasic pattern, whereas Nav1.7R-/- mice (n = 8) showed no phase I (first hour) and a reduced phase II (P < 0.05 at 0.25, 0.5, 1, 2, 6.5, and 8 h, ANOVA). (B) Inflammatory pain is normal in Nav1.8Cre mice. Analysis of behavior of Nav1.8Cre+/- (black) and C57BL/6 (white) mice in models of inflammatory pain. (Ba) Behavior of Nav1.8Cre+/- (n = 6) and C57BL/6 (n = 6) mice after intraplantar injection of 20 μl of 5% formalin was not different between groups in phase I (107 ± 12.6 s and 96.1 ± 10.3 s, respectively; P = 0.51) and phase II (230 ± 47.7 and 290 ± 45.4 s, respectively; P = 0.38, t test). (Bb) Thermal hyperalgesia after intraplantar injection of 20 μl of CFA was not different in Nav1.8Cre+/- (0.58 ± 0.05, n = 6) and WT (0.55 ± 0.05, n = 6) littermates (P = 0.79, ANOVA). (Bc) Mechanical allodynia after intraplantar injection of 20 μl of CFA was not different in Nav1.8Cre+/- (0.30 ± 0.16, n = 6) and WT (0.27 ± 0.04, n = 6) littermates (P = 0.74, ANOVA). (Bd) Thermal hyperalgesia induced by intraplantar injection of 20 μl of 2% carrageenan was not different in Nav1.8Cre+/- (0.40 ± 0.26, n = 9) and C57BL/6 (0.36 ± 0.03, n = 7) mice (P = 0.31, two-way ANOVA). (Be) Thermal hyperalgesia induced by intraplantar injection of 500 ng of NGF was not different in Nav1.8Cre+/- (0.58 ± 0.02) (n = 6) and C57BL/6 (0.56 ± 0.03) (n = 6) mice (P = 0.83, two-way ANOVA).